A controlled clinical trial of fluspirilene, a long-acting injectable neuroleptic, in schizophrenic patients with acute exacerbation.
A 4-week double-blind controlled clinical trial was carried out in which fluspirilene, an injectable diphenylbutylpiperidine neuroleptic given weekly, was compared to chlorpromazine in the treatment of 40 newly admitted schizophrenic patients with acute exacerbation. Similar therapeutic improvement was obtained with both drugs, but men needed a significantly higher mean dose of fluspirilene (23 mg/week) than women (13 mg/week). Fluspirilene induced more parkinsonism than chlorpromazine, but less drowsiness, dizziness, and dry mouth. The difference between the sexes in the potency of fluspirilene and its greater potential to induce parkinsonism may be related to its lesser presynaptic and D1-dopamine receptor blocking properties. The low incidence of autonomic side effects confirms the relative specificity of fluspirilene for dopamine receptors.
D000328:Adult; D000367:Age Factors; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D002746:Chlorpromazine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005484:Fluspirilene / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D008297:Male; D011388:Prolactin / Q000097:blood; D011897:Random Allocation; D012559:Schizophrenia / Q000188:drug therapy*; D012737:Sex Factors; D013141:Spiro Compounds / Q000627:therapeutic use*
D013141:Spiro Compounds; D011388:Prolactin; D005484:Fluspirilene; D002746:Chlorpromazine